RedHill Biopharma | RDHL - Selling And Administration Expenses

Stock Price
0.87
Daily Change
-0.01 -1.14%
Monthly
-14.71%
Yearly
-66.02%
Q1 Forecast
0.84

RedHill Biopharma reported $4.48M in Selling and Administration Expenses for its fiscal quarter ending in March of 2024.





Selling And Administration Expenses Change Date
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.33M 50K Sep/2025
Cronos Group USD 19.45M 4.9M Dec/2025
RedHill Biopharma USD 4.48M 1.52M Mar/2024